peeling skin syndrome, acral type

(redirected from APSS)
Also found in: Acronyms.

peeling skin syndrome, acral type

An extremely rare autosomal recessive genodermatosis (OMIM:609796) characterised by shedding of the outer epidermis, especially of the dorsa of the hands and feet, which is exacerbated by increase ambient temperature and/or humidity. 

Molecular pathology
Caused by defects of TGM5, which encodes a transglutaminase that catalyses cross-linking in proteins between glutamine and lysine residues.
References in periodicals archive ?
DCMA has provided APSS to PBL-related processes and capabilities, including supply chain management, demand forecasting, obsolescence management, logistics surveillance, and partnering arrangements.
Somaxon's Oral Presentation at APSS in Minneapolis, MN, on Wednesday, June 15(th)
In a related APSS poster presentation, investigators described a study in which they sought to quantify the proportion of MOTN insomnia patients who would be suitable candidates for treatment with a rapidly effective and short-acting agent.
Results of a new survey that found that insomnia was common in the nursing community, previously announced by Alertness Solutions, were presented at the APSS meeting.
Previously-released data from Somaxon's Phase 3 clinical development program for SILENOR[TM] presented at the APSS 2008 annual meeting in oral presentation or poster form are as follows:
This press release, and the above-mentioned materials from Vanda's APSS presentation to be made available on Vanda's website, contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Vanda's plans for VEC-162 and its other product candidates.
A summary of the Somaxon Pharmaceuticals APSS 2008 presentations is as follows:
APSS was formed on April 1, 2004, and is chartered with extending the company's reach into advanced propulsion, composite and space systems technologies.
Also presented at APSS were the results of a four-week, 153-patient, multi-center, double-blind trial assessing the safety and efficacy of LUNESTA versus placebo in patients with insomnia and co-existing rheumatoid arthritis (RA).
Don Shaffer, group vice president, APSS, said PSI's capabilities strengthen the company's portfolio as a system level integrator for satellite structures and other spacecraft.
Three studies on indiplon immediate release are being presented at APSS, including:
The acquisition of APSS also further extends First Data's capabilities and service offering in the areas of smart card development, ATM management and debit card processing.